Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Equity Raise PALSONIFY Launch And Positive Atumelnant Data [Yahoo! Finance]
Crinetics Pharmaceuticals, Inc. (CRNX)
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
launch revenue above US$5 million and positive Phase 2 atumelnant data in congenital adrenal hyperplasia. See our latest analysis for Crinetics Pharmaceuticals. The recent equity raise, PALSONIFY launch update and positive atumelnant Phase 2 readout come on top of an 18.52% 90 day share price return and a 274.74% five year total shareholder return, suggesting momentum has been building over both shorter and longer periods. If this kind of move in rare disease biotech interests you, it could be worth scanning other healthcare stocks that might be setting up for their own catalysts. With CRNX trading at US$53.25 against an US$83.00 analyst target and an intrinsic value marker that flags roughly a 90% discount, you have to ask: is this a genuine mispricing, or is the market already baking in future growth? At a last close of US$53.25, Crinetics Pharmaceuticals is on a P/B of 4.7x, which screens as good value versus direct peers but richer than the wider US pharmaceuticals group
Show less
Read more
Impact Snapshot
Event Time:
CRNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRNX alerts
High impacting Crinetics Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRNX
News
- Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral [Yahoo! Finance]Yahoo! Finance
- Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Crinetics Pharmaceuticals (NASDAQ:CRNX) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $67.00 price target on the stock.MarketBeat
- Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target lowered by analysts at Citizens Jmp from $108.00 to $105.00. They now have a "market outperform" rating on the stock.MarketBeat
- Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common StockGlobeNewswire
CRNX
Earnings
- 11/6/25 - Miss
CRNX
Sec Filings
- 1/13/26 - Form 8-K
- 1/7/26 - Form 4
- 1/7/26 - Form 8-K
- CRNX's page on the SEC website